December 17, 2014 6:02 AM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ImmunoCellular Therapeutics, Ltd.("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Patent and TrademarkOffice (USPTO) has issued a key patent covering ImmunoCellular's productcandidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targetingsix tumor antigens that are commonly expressed on glioblastoma. The claims ofUS Patent No. 8,871,211, which issued October 28, 2014, include methods oftreating neural cancer by administering a dendritic cell compositioncomprising peptide epitopes of the six tumor antigens of ICT-107. The claimsspecifically cover administration of the recited dendritic cell composition toa patient suffering from glioma, which is inclusive of glioblastomamultiforme."This patent provides important protection for ICT-107, and adds toImmunoCellular's intellectual property estate for our cancer vaccineportfolio," said Andrew Gengos, ImmunoCellular Chief Executive Officer.The ICT-107 patent was issued to Cedars Sinai Medical Center, and isexclusively licensed to ImmunoCellular Therapeutics.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.